Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.76 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3922456 | 0.86 | GRM5 (1.00) | GRM5IRAK4KDM4EALDH1A1MAPT | |
| SCHEMBL30795243 | 0.86 | GRM5 (1.00) | GRM5IRAK4KDM4EALDH1A1MAPT | |
| SCHEMBL12410532 | 0.86 | GRM5 (0.60) | GRM5IRAK4 | |
| SCHEMBL3931395 | 0.83 | GRM5 (0.72) | GRM5IRAK4 | |
| SCHEMBL3934307 | 0.79 | GRM5 (0.70) | GRM5IRAK4PDE10A | |
| SCHEMBL2123868 | 0.78 | GRM5 (0.55) | GRM5KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL3923984 | 0.77 | GRM5 (0.60) | GRM5TSHRPDE10A | |
| SCHEMBL3920040 | 0.77 | GRM5 (0.64) | GRM5IRAK4KDM4EALDH1A1PDE10A | |
| SCHEMBL30795872 | 0.77 | GRM5 (0.64) | GRM5IRAK4KDM4EALDH1A1PDE10A | |
| SCHEMBL15945076 | 0.76 | GRM5 (0.66) | GRM5PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458383-B1 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2007-11-21 | — | — | EP | claimed |
| EP-1458383-A4 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME LLC | 2005-02-03 | — | — | US | claimed |
| EP-1458383-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003051833-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | claimed |
| US-20120220453-A1 | PESTICIDAL COMPOSTIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220453-A1 | PESTICIDAL COMPOSTIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116246-A2 | PESTICIDAL COMPOSTIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2012-08-30 | — | — | WO | disclosed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569592-B2 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| WO-2003051833-A2 | HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026963-A1 | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | GRM5 1/4885IRAK4 2589/4885KDM4E 2688/4885 |
| US-20120220453-A1 | PESTICIDAL COMPOSTIONS AND PROCESSES RELATED THERETO | DDT, ACHE, NOTUM | GRM5 3896/4885IRAK4 3905/4885KDM4E 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.